DRST Logo EBMT Logo EBMT SURVEY ON TRANSPLANT ACTIVITY 2016
Table 1: Report the number of patients (both adult and/or pediatric) receiving their 1st allogeneic and/or 1st autologous transplant in your centre in 2016
Table 2: Report the number of patients receiving non HSCT cellular therapies in 2016 by indication and cell type.
Further help can be found in the guidelines or at www.ebmt.org - activity survey link.

Table 1:
(adults and/or pediatric)
Allogeneic Autologous Total   No.
allo
after
auto
Related Unrelated         
HLA - id sibling Twin Haplo
(>= 2 loci
mismatch)
Other family
member
Allo Auto Total
Indication BM PBSC Cord BM PBSC BM PBSC BM PBSC Cord BM PBSC Cord BM PBSC Cord
1 AML 1st CR        
2   non 1st CR        
3   therapy related        
4   trans. from MDS/MPN        
5 ALL 1st CR        
6   non 1st CR        
7 CML 1st cP        
8   not 1st cP        
9 MDS or MDS/MPN        
10 MPN        
11 CLL incl. PLL        
12 PCD - Myeloma        
13 PCD - other        
14 HD        
15 NHL        
16 Neuroblastoma        
17a Soft tissue sarcoma        
17b Ewing sarcoma        
18 Germ cell tumor        
19 Breast cancer        
20 Other solid tumor        
21 BM aplasia - SAA        
22 BM aplasia - other        
23 Thalassemia        
24 Sickle cell        
25 Primary Immune deficiency        
26 Inh. disorder of metabolism        
27 Autoimmune disease        
28 Others (incl. Histiocytosis)        
29 Total 1st HSCT (row 1-28)                                          
30 No. Additional HSCT          
31 Total ALL HSCT
(= total of row 29 + 30)
                                         
32        

Fill in number of patients age <18 automatically:
 

33 Number of patients receiving DLI infusions in 2016 For graft enhancement/failure: For residual disease: For relapse: Per protocol:
34 Number of Non Myeloablative transplants in 2016    

Table 2: Non HSCT Cellular Therapies using manipulated or selected cells in 2016
  Indication for treatment
(number of patients)
MSC NK cells Selected/
expanded
T cells or CIK
Regulatory
T cells
(TREGS)
Genetically
modified
T cells
Dendritic
cells
Expanded
CD34+ cells
Genetically
modified
CD34+ cells
Other
Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto Allo Auto
35 GvHD
36 Graft enhancement/failure
37 Autoimmune disease
38 Genetic disease
39 Infection
40 Malignancy
41 Regenerative medicine

DRST-CIC 0 EBMT-CIC Kommentar
Kontaktperson